Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

AEZS $0.58 0.0142 +2.51%
TCON $11.98 0.2400 +2.04%
AGEN $7.24 0.1200 +1.69%
MYGN $34.00 0.4100 +1.22%
SNY $52.28 0.5300 +1.02%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

ATRA $48.29 -11.6000 -19.37%
CLDX $25.33 -4.7700 -15.85%
CBMG $25.12 -4.3900 -14.88%
CALA $11.54 -1.8700 -13.94%
CNDO $3.44 -0.5300 -13.35%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next > | Last >>

Lilly's CYRAMZA® (ramucirumab) Receives Fourth FDA Approval

(Lilly) Apr 24, 2015 - CYRAMZA now approved in the U.S. for use with FOLFIRI in second-line treatment of metastatic colorectal cancer.
read corporate press release 

Trial of Radioactive Implants Offers Improved Prostate Cancer Survival

(The Guardian [UK]/Press Association) Apr 26, 2015 - A prostate cancer treatment using permanently implanted radioactive “seeds” doubles rates of five-year tumour-free survival compared with conventional high-dose radiotherapy, a study has found.
read article 

Biogen Drops as Profit Disappoints Amid Sluggish Tecfidera Sales

(Bloomberg) Apr 24, 2015 - Biogen Inc., the maker of multiple sclerosis drug Tecfidera, fell the most in six months after reporting profit that trailed analysts’ estimates as sales of its top drug slowed in the U.S. and in Germany.
read article 

TD2 and Navigating Cancer Partner to Bring Patient-Reported Outcomes to Clinical Trials Through a Cutting-Edge Mobile Application

(Navigating Cancer) Apr 20, 2015 - TD2, the precision oncology CRO, and Navigating Cancer, the leading web-based patient care and engagement solution for oncology clinics, today announced a partnership to improve the engagement of patients in clinical trials and bring patient-reported outcomes to the clinical trials process.
read press release 

Mylan Raises Its Offer for Perrigo, Which Rejects It

(New York Times/DealBook blog) Apr 24, 2015 - The drug maker Mylan on Friday raised its unsolicited offer for Perrigo, the Irish maker of store brand drugs, as it seeks to fend off its own unwanted suitor in Teva, the Israeli pharmaceutical company.
read article 

AbbVie Hepatitis C Drug Granted Priority FDA Review

(Wall Street Journal) Apr 24, 2015 - The U.S. Food and Drug Administration on Friday granted priority review to AbbVie Inc.’s drug to treat adult patients with chronic genotype 4 hepatitis C, as competition among makers of hepatitis drugs intensifies.
read article (paid subscription required) 

FDA Grants Priority Review to Boehringer's Drug to Reverse Blood Thinning

(Reuters) Apr 23, 2015 - Boehringer Ingelheim Pharmaceuticals Inc said its drug to reverse blood thinning was granted a priority review status by the U.S. Food and Drug Administration, accelerating the regulatory process by four months.
read article 

Merck’s Hepatitis C Drugs May Challenge Gilead and AbbVie

(Bloomberg) Apr 24, 2015 - Merck & Co. said its experimental hepatitis C drug combination cured 95 percent of previously untreated patients in a late-stage study that suggests it may be competitive with Gilead Sciences Inc. and AbbVie Inc. medicines.
read article 

Angry Over Drug Prices, More States Push Bills for Pharma to Disclose Costs

(Wall Street Journal/Pharmalot blog) Apr 24, 2015 - Should drug makers be required to disclose their costs to justify rising prices?
read article (paid subscription required) 

Breast Cancer Gene Test Becoming More Afforrdable, Accessible

(KSAT 12 ABC [San Antonio, TX]) Apr 23, 2015 - Doctors at the Cancer Therapy and Research Center at the University of Texas Health Science Center are awaiting the reaction to news that several companies will be dropping the price of breast cancer gene testing dramatically, making the BRCA 1 and 2 test accessible to many who could not afford it.
read article 

Targazyme, Inc., Announces FDA Concurrence on Targazyme's Special Protocol Assessment for a Planned Phase 3 Registration Trial for the Treatment of Patients With Hematologic Malignancies

(Yahoo! Finance) Apr 23, 2015 - Targazyme, Inc., announced today that the U.S. Food and Drug Administration (FDA) and Targazyme have reached concurrence on the company's Special Protocol Assessment (SPA) application for its Phase 3 registration trial.
read article 

Thyroid Group Issues Guidelines for Kids' Nodule Management

(MedPage Today) Apr 23, 2015 - Range of options preferred over 'one-size-fits-all' treatments.
read article (free registration required) 

ONO Submits Additional Indication Application for OPDIVO® (Nivolumab) for the Treatment of Patients with Unresectable, Advanced or Recurrent Non-Small Cell Lung Cancer (Except Non-Squamous Cell Carcinoma)

(ONO) Apr 22, 2015 - ONO PHARMACEUTICAL CO., LTD. announced today that it has submitted an additional indication application for the human anti-human programmed cell death-1 (PD-1) monoclonal antibody “OPDIVO® 20mg, 100mg Inj.”
read corporate press release 

Bayer Submits Marketing Authorization for Radium-223 Dichloride to Treat Prostate Cancer with Bone Metastases in Japan

(Bayer) Apr 24, 2015 - Bayer HealthCare has submitted an application for marketing authorization to the Ministry of Health, Labour and Welfare (MHLW) in Japan for radium-223 dichloride (radium-223) solution for injection for the treatment of prostate cancer patients with bone metastases.
read corporate press release 

Animal Testing and Its Gifts To Humans

(Wall Street Journal) Apr 23, 2015 - Patients with aggressive brain tumors finally have reason for hope. Thanks to the work of scientists and physicians at Duke University, an experimental new treatment for glioblastoma multiforme, or GBM—an aggressive tumor that kills about 12,000 people in the U.S. each year—is saving the lives of patients who, just months ago, had little hope of survival.
read article (paid subscription required) 

Refusal of the Marketing Authorisation For Lympreva (dasiprotimut-T)

(EMA) Apr 23, 2015 - On 23 April 2015, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Lympreva, intended for the treatment of patients with follicular non-Hodgkin’s lymphoma.
read article 

Insurance Coverage for Mammograms Jeopardized By New Guidelines, Congresswoman and Breast Cancer Survivor Says

(Washington Post) Apr 23, 2015 - Earlier this week, the U.S. Preventive Services Task Force, an independent group of doctors and health-care experts, issued draft recommendations on mammography for women at various ages.
read article (free registration required) 

Oncologist Highlights Primary Reasons for the High Cost of Cancer Care

(AJMC) Apr 23, 2015 - With the rising prices of innovative oncology treatments, many of which fall under specialty pharmaceuticals, curbing the cost of care is high on the agenda of healthcare providers.
read article 

Payers and Providers Discuss Pros and Cons of Oncology Payment Reform

(AJMC) Apr 23, 2015 - A general session at the Community Oncology Conference, Community Oncology 2.0, Moving Forward on Payment Reform, was a panel discussion that saw participation by 2 providers and a payer.
read article 

Can a Compound in Red Wine Help Fight Cancer? How Supplements Can Be Promising Disease-Fighters

(Huffington Post) Apr 23, 2015 - In the war against cancer, we've taken many steps forward, thanks to science and treatments like radiation and chemotherapy.
read article 

Combo Approach Fails in Liver Cancer Trial

(MedPage Today) Apr 23, 2015 - Combining an angiogenesis inhibitor and transcatheter arterial chemoembolization doesn't work.
read article (free registration required) 

New Data Shows Irreversible Electroporation Nearly Doubles Overall Survival of Patients with Locally Advanced Pancreatic Cancer When Added to Standard Therapy

(Sacramento Business Journal) Apr 24, 2015 - University of Louisville announced today results from the Soft Tissue Ablation Registry (STAR), demonstrating that irreversible electroporation (IRE) with the NanoKnife®System, in combination with chemotherapy, doubled the overall survival rate of locally advanced (Stage III) pancreatic cancer patients to nearly 24 months.
read article 

Standard Clinical Assays Can Obscure The Diversity Of Breast Cancer Subtypes

(Clinical Leader) Apr 24, 2015 - Classification systems that categorize breast cancers based on estrogen receptor (ER), progesterone receptor (PR), and HER2 expression levels may obscure the heterogeneity of other key tumor features, according to a new study published in The Oncologist on April 23, 2015.
read article 

An End to Cancer Pain? Dentistry Researcher Finds the Pain Trigger

(University of Toronto - Faculty of Dentistry) Apr 23, 2015 - A new study led by Dr. David Lam has discovered the trigger behind the most severe forms of cancer pain. Released in top journal Pain this month, the study points to TMPRSS2 as the culprit: a gene that is also responsible for some of the most aggressive forms of androgen-fuelled cancers.
read article 

'Humanized' Mice Will Lead to Better Testing of Cancer Immunotherapies

(UCCC/In the Lab blog) Apr 23, 2015 - Human tumours grown in mouse models have long been used to test promising anti-cancer therapies. However, when a human tumour is transplanted into a mouse, the mouse immune system must be knocked down so that it doesn't attack the foreign tumour tissue, thus allowing the tumour to grow.
read article